What type of study is this?

This is a Human Clinical Trial study.

December 8, 2025Blood

Clinical experience with efanesoctocog alfa in patients with uncover needs on emicizumab

View Full Paper

Ask AI

Bookmark

Joint bleeding control improved significantly with efanesoctocog alfa in male patients with hemophilia A, enhancing their quality of life.
Patients experienced reduced pain levels and increased hemostatic control without safety concerns after treatment transition.
Case report included four adult males, highlighting the necessity of selecting appropriate levels of factor VIII for effective management.
Switching from emicizumab to efanesoctocog alfa introduced challenges in monitoring factor levels, emphasizing the need for accessible chromogenic assays.

No takes yet. Share an insight, caveat, or question.

Case report shows increased bleeding control in adult males with hemophilia A, indicating efanesoctocog alfa benefits over emicizumab.

Herrero et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark